睿知中国医院研究地图
候选清单

正在招募淋巴瘤III期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

ClinicalTrials.gov 上登记的一项淋巴瘤开放试验。牵头方不是本站收录的医院;本站收录的 20 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 20

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心贵州医科大学附属医院Affiliated Hospital of Guizhou Medical University贵阳医院页面
  2. 研究中心南通大学附属医院Affiliated Hospital of Nantong University南通医院页面
  3. 研究中心安徽省肿瘤医院Anhui Provincial Cancer Hospital合肥医院页面
  4. 研究中心重庆大学附属肿瘤医院Chongqing University Cancer Hospital重庆医院页面
  5. 研究中心厦门大学附属第一医院First Affiliated Hospital of Xiamen University厦门医院页面
  6. 研究中心吉林大学第一医院First Hospital of Jilin University长春医院页面
  7. 研究中心复旦大学附属肿瘤医院Fudan University Shanghai Cancer Center上海医院页面
  8. 研究中心福建省肿瘤医院Fujian Cancer Hospital福州医院页面
  9. 研究中心广西医科大学附属肿瘤医院Guangxi Medical University Cancer Hospital南宁医院页面
  10. 研究中心湖北省肿瘤医院Hubei Cancer Hospital武汉医院页面
  11. 研究中心中国医学科学院血液病医院(血液学研究所)Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC天津医院页面
  12. 研究中心江西省肿瘤医院Jiangxi Cancer Hospital南昌医院页面
  13. 研究中心北京大学肿瘤医院Peking University Cancer Hospital北京医院页面
  14. 研究中心北京大学第三医院Peking University Third Hospital北京医院页面
  15. 研究中心山东省肿瘤医院Shandong Cancer Hospital and Institute济南医院页面
  16. 研究中心山西省肿瘤医院Shanxi Cancer Hospital太原医院页面
  17. 研究中心四川省肿瘤医院Sichuan Cancer Hospital成都医院页面
  18. 研究中心中山大学肿瘤防治中心Sun Yat-sen University Cancer Center广州医院页面
  19. 研究中心四川大学华西医院West China Hospital成都医院页面
  20. 研究中心南方医科大学珠江医院Zhujiang Hospital广州医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT06717347,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 6

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(6 项)收起清单
  1. 18 岁 至 未注明;性别:不限

    登记记录的入选字段

  2. Has histologically confirmed diagnosis of diffuse large B-cell lymphoma (DLBCL), by prior biopsy, based on local testing according to the WHO classification of neoplasms of the hematopoietic and lymphoid tissues

    入选标准第 1 条

  3. Who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy and have undetectable HBV viral load prior to randomization

    入选标准第 7 条

  4. Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 assessed within 7 days before randomization

    入选标准第 4 条

  5. Has positron emission tomography (PET) positive disease at screening, defined as 4 to 5 on the Lugano 5-point scale

    入选标准第 2 条

  6. HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease

    排除标准第 8 条

    Known additional malignancy that is progressing or has required active treatment within the past 2 years

    排除标准第 11 条

    Has concurrent active HBV (defined as HBsAg positive and detectable HBV DNA) and HCV (defined as anti-HCV antibody positive and detectable HCV ribonucleic acid (RNA)) infection

    排除标准第 15 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);化验:血常规、肝肾功能;怀孕、哺乳与避孕。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06717347,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Has histologically confirmed diagnosis of diffuse large B-cell lymphoma (DLBCL), by prior biopsy, based on local testing according to the WHO classification of neoplasms of the hematopoietic and lymphoid tissues
  2. Has positron emission tomography (PET) positive disease at screening, defined as 4 to 5 on the Lugano 5-point scale
  3. Has received no prior treatment for their DLBCL
  4. Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 assessed within 7 days before randomization
  5. Has an ejection fraction ≥45% as determined by either echocardiogram (ECHO) or multigated acquisition (MUGA)
  6. Human immunodeficiency virus (HIV) infected participants must have well controlled HIV on antiretroviral therapy (ART)
  7. Who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy and have undetectable HBV viral load prior to randomization
  8. Participants with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at screening

排除标准:Exclusion Criteria:

  1. Has a history of transformation of indolent disease to DLBCL
  2. Has received a diagnosis of primary mediastinal B-cell lymphoma (PMBCL) or Grey zone lymphoma
  3. Has Ann Arbor Stage I DLBCL
  4. Has clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (<6 months prior to enrollment), myocardial infarction (<6 months prior to enrollment), unstable angina, congestive heart failure (New York Heart Association Classification Class ≥II), or serious cardiac arrhythmia requiring medication
  5. Has clinically significant pericardial or pleural effusion
  6. Has ongoing Grade >1 peripheral neuropathy
  7. Has a demyelinating form of Charcot-Marie-Tooth disease
  8. HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
  9. Has ongoing corticosteroid therapy
  10. Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines is allowed
  11. Known additional malignancy that is progressing or has required active treatment within the past 2 years
  12. Known active central nervous system (CNS) lymphoma
  13. Has active autoimmune disease that has required systemic treatment in the past 2 years
  14. Has active infection requiring systemic therapy
  15. Has concurrent active HBV (defined as HBsAg positive and detectable HBV DNA) and HCV (defined as anti-HCV antibody positive and detectable HCV ribonucleic acid (RNA)) infection
  16. Has history of allogeneic tissue/solid organ transplant

引自 ClinicalTrials.gov, NCT06717347, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06717347,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT06717347